
Opinion|Videos|September 30, 2024
Mechanism of Action: Luspatercept vs Epoetin Alfa in LR-MDS
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these differences may correlate with clinical benefits for patients with lower-risk myelodysplastic syndromes (LR-MDS).
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
Please discuss how the mechanism of action differs between luspatercept and epoetin alfa and how it may correlate with clinical benefit for patients with LR-MDS.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5
















